Integrated OTC Stock Today

INBP -  USA Stock  

USD 1.08  0.01  0.92%

Integrated Biopharma is selling at 1.08 as of the 25th of October 2021; that is -0.92 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.06. Integrated Biopharma has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Integrated Biopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of August 2021 and ending today, the 25th of October 2021. Please note, there could be an existing legal relationship between Integrated Biopharma (INBP) and Integrated Biopharma (IHTC). Click here to learn more.
 Market Performance
3 of 100
  Odds Of Distress
Over 51
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. The company has 29.77 M outstanding shares of which 0 shares are currently shorted by private and institutional investors with about 0.0 trading days to cover. More on Integrated Biopharma

Integrated Biopharma OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Integrated Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Integrated Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Integrated Biopharma has some characteristics of a very speculative penny stock
Integrated Biopharma has very high historical volatility over the last 90 days
Integrated Biopharma has high likelihood to experience some financial distress in the next 2 years
Integrated Biopharma has a frail financial position based on the latest SEC disclosures
About 68.0% of the company shares are held by company insiders
Latest headline from www.marketscreener.com: I-Mab Expands U.S. Footprint with New RD Site in San Diego - Marketscreener.com
Integrated Biopharma Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Integrated Biopharma SEC Filings
Integrated Biopharma SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameIntegrated Biopharma
Related EntityIHTC (Integrated Biopharma)
Chairman, CEO and PresGerald Kay  (View All)
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Integrated Biopharma based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Integrated Biopharma financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares29.9 M29.7 M
Slightly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted33.8 M32.1 M
Sufficiently Up
Increasing
Slightly volatile
Net Cash Flow from Operations3.3 MM
Significantly Up
Increasing
Slightly volatile
Total Assets23.6 M25.4 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities13.7 M11.1 M
Fairly Up
Decreasing
Slightly volatile
Current Assets17.3 M18 M
Sufficiently Down
Increasing
Slightly volatile
Current Liabilities10 M9.2 M
Significantly Up
Decreasing
Stable
Total Debt8.5 MM
Significantly Up
Decreasing
Slightly volatile
Return on Average Assets0.260.316
Significantly Down
Increasing
Slightly volatile
Gross Margin0.150.149
Slightly Up
Increasing
Slightly volatile
Asset Turnover2.492.506
Slightly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Integrated Biopharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Financial Strength
Integrated Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Integrated Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Integrated Biopharma's financial leverage. It provides some insight into what part of Integrated Biopharma's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Integrated Biopharma's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Integrated Biopharma deploys its capital and how much of that capital is borrowed.
Liquidity
Integrated Biopharma cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 8.19 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Integrated Biopharma has a current ratio of 1.4, which is within standard range for the sector.

Operating Cash Flow

3.29 MillionShare
Integrated Biopharma [INBP] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Integrated Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 32.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Integrated Biopharma's market, we take the total number of its shares issued and multiply it by Integrated Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Integrated Biopharma conducts business under Consumer Defensive sector and is part of Packaged Foods industry. The entity has 29.77 M outstanding shares of which 0 shares are currently shorted by private and institutional investors with about 0.0 trading days to cover. Integrated Biopharma currently holds about 105 K in cash with 128 K of positive cash flow from operations.
Check Integrated Biopharma Probability Of Bankruptcy
Ownership
Integrated Biopharma has a total of twenty-nine million seven hundred seventy thousand outstanding shares. Integrated Biopharma retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 67.5 (percent) of Integrated Biopharma outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Integrated Ownership Details

Integrated Stock Price Odds Analysis

What are Integrated Biopharma's target price odds to finish over the current price? Contingent on a normal probability distribution, the odds of Integrated Biopharma jumping above the current price in 90 days from now is about 22.94%. The Integrated Biopharma probability density function shows the probability of Integrated Biopharma otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Integrated Biopharma has a beta of -0.1283. This usually indicates as returns on benchmark increase, returns on holding Integrated Biopharma are expected to decrease at a much lower rate. During the bear market, however, Integrated Biopharma is likely to outperform the market. Additionally, the company has an alpha of 0.0555, implying that it can generate a 0.0555 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 1.08HorizonTargetOdds Up 1.08 
76.90%90 days
 1.08 
22.94%
Based on a normal probability distribution, the odds of Integrated Biopharma to move above the current price in 90 days from now is about 22.94 (This Integrated Biopharma probability density function shows the probability of Integrated OTC Stock to fall within a particular range of prices over 90 days) .

Integrated Biopharma Historical Income Statement

Integrated Biopharma Income Statement is one of the three primary financial statements used for reporting Integrated's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Integrated Biopharma revenue and expense. Integrated Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Integrated Biopharma Selling General and Administrative Expense is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Selling General and Administrative Expense of 3.7 Million. As of 25th of October 2021, Weighted Average Shares is likely to grow to about 29.9 M, while Operating Income is likely to drop about 4.7 M. View More Fundamentals

Integrated Stock Against Markets

Picking the right benchmark for Integrated Biopharma otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Integrated Biopharma otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Integrated Biopharma is critical whether you are bullish or bearish towards Integrated Biopharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Integrated Biopharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Integrated Biopharma Corporate Directors

Integrated Biopharma corporate directors refer to members of an Integrated Biopharma board of directors. The board of directors generally takes responsibility for the Integrated Biopharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Integrated Biopharma's board members must vote for the resolution. The Integrated Biopharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Robert Canarick - Independent DirectorProfile
Carl DeSantis - DirectorProfile
Joseph LaPlaca - DirectorProfile
William Milmoe - DirectorProfile
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.